China’s Livongo Incarey Closes Series B+ at USD 30 Mn

Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis

‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’

Cellatopia Secures Nearly CNY Ten Mn in Seed Funding

EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).

Hengrui's MSCI ESG Rating Upgraded to A

Hengrui, as one of the leading pharmaceutical companies in innovation, has achieved continuous improvement in its MSCI ESG rating to "A" level, placing it at the forefront of the pharmaceutical industry in China.

Lanja has completed the Series A funding of hundred millions CNY

Shanghai Lanja Medical Technology Co., Ltd (“Lanja”) recently has announced the completion of the Series A funding of hundred millions CNY.

RabPharma has completed the Series A+ funding of hundred millions CNY

Zhongshan RabPharma Biopharmaceutical Co., Ltd. (“RabPharma”) recently has announced the completion of the Series A+ funding of hundred millions CNY.